HSPD1 and osteosarcoma: MK2206 treatment significantly reduced the levels of p-AKT, p-mTOR, N-cadherin, and vimentin in osteosarcoma cells, while overexpression of HSPD1 partially abrogated these inhibitory effects (Figure 7J-K, N-O).